A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02915172

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:31.462599+00:00

Published At

2017-06-26T00:00:00+00:00

Record Updated At

2017-06-26

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Advanced Cancer", "Malignant Neoplasm of Breast", "Malignant Neoplasms of Bone and Articular Cartilage", "Malignant Neoplasms of Digestive Organs", "Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System", "Malignant Neoplasms of Female Genital Organs", "Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites", "Malignant Neoplasms of Independent (Primary) Multiple Sites", "Malignant Neoplasms of Lip Oral Cavity and Pharynx", "Malignant Neoplasms of Male Genital Organs", "Malignant Neoplasms of Mesothelial and Soft Tissue", "Malignant Neoplasms of Respiratory and Intrathoracic Organs", "Malignant Neoplasms of Thyroid and Other Endocrine Glands", "Malignant Neoplasms of Urinary Tract"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-06-26"

protocolSection.identificationModule.nctId

"NCT02915172"

protocolSection.identificationModule.officialTitle

"A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies"

protocolSection.statusModule.overallStatus

"WITHDRAWN"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Advanced Cancer (protocolSection.conditionsModule.conditions)
• Malignant Neoplasm of Breast (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Bone and Articular Cartilage (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Digestive Organs (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Female Genital Organs (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Independent (Primary) Multiple Sites (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Lip Oral Cavity and Pharynx (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Male Genital Organs (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Mesothelial and Soft Tissue (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Respiratory and Intrathoracic Organs (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Thyroid and Other Endocrine Glands (protocolSection.conditionsModule.conditions)
• Malignant Neoplasms of Urinary Tract (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.